Cost analysis of intra-arterial versus intra-venous delivery of bevacizumab for the treatment of recurrent glioblastoma multiforme

Jan Karl Burkhardt; Benjamin J. Shin; Cody D. Schlaff; Howard Riina; John A. Boockvar

Cost analysis of intra-arterial versus intra-venous delivery of bevacizumab for the treatment of recurrent glioblastoma multiforme

Jan Karl Burkhardt
, Benjamin J. Shin
, Cody D. Schlaff
, Howard Riina
, John A. Boockvar

Department of Radiology

Research output: Contribution to journal › Article › peer-review

11 Scopus citations

Abstract

Intra-arterial bevacizumab (IA BV) has been recently identified to be safe in the treatment of recurrent GBM. In this study, we sought to perform a cost analysis of IA BV versus IV BV especially also taking account of patient progression free survival (PFS) and overall survival (OS). We show that IA BV is significantly more cost effective than conventional IV therapy.

Original language	English (US)
Pages (from-to)	183-186
Number of pages	4
Journal	Journal of Experimental Therapeutics and Oncology
Volume	9
Issue number	3
State	Published - 2011

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

All Science Journal Classification (ASJC) codes

Pharmacology
Drug Discovery
Cancer Research

Cite this

@article{cb4ec2ea44bf4abe8f27bfcdd02ca451,

title = "Cost analysis of intra-arterial versus intra-venous delivery of bevacizumab for the treatment of recurrent glioblastoma multiforme",

abstract = "Intra-arterial bevacizumab (IA BV) has been recently identified to be safe in the treatment of recurrent GBM. In this study, we sought to perform a cost analysis of IA BV versus IV BV especially also taking account of patient progression free survival (PFS) and overall survival (OS). We show that IA BV is significantly more cost effective than conventional IV therapy.",

author = "Burkhardt, \{Jan Karl\} and Shin, \{Benjamin J.\} and Schlaff, \{Cody D.\} and Howard Riina and Boockvar, \{John A.\}",

year = "2011",

language = "English (US)",

volume = "9",

pages = "183--186",

journal = "Journal of Experimental Therapeutics and Oncology",

issn = "1359-4117",

publisher = "Old City Publishing",

number = "3",

}

TY - JOUR

T1 - Cost analysis of intra-arterial versus intra-venous delivery of bevacizumab for the treatment of recurrent glioblastoma multiforme

AU - Burkhardt, Jan Karl

AU - Shin, Benjamin J.

AU - Schlaff, Cody D.

AU - Riina, Howard

AU - Boockvar, John A.

PY - 2011

Y1 - 2011

N2 - Intra-arterial bevacizumab (IA BV) has been recently identified to be safe in the treatment of recurrent GBM. In this study, we sought to perform a cost analysis of IA BV versus IV BV especially also taking account of patient progression free survival (PFS) and overall survival (OS). We show that IA BV is significantly more cost effective than conventional IV therapy.

AB - Intra-arterial bevacizumab (IA BV) has been recently identified to be safe in the treatment of recurrent GBM. In this study, we sought to perform a cost analysis of IA BV versus IV BV especially also taking account of patient progression free survival (PFS) and overall survival (OS). We show that IA BV is significantly more cost effective than conventional IV therapy.

UR - https://www.scopus.com/pages/publications/84455163173

UR - https://www.scopus.com/pages/publications/84455163173#tab=citedBy

M3 - Article

C2 - 22070049

AN - SCOPUS:84455163173

SN - 1359-4117

VL - 9

SP - 183

EP - 186

JO - Journal of Experimental Therapeutics and Oncology

JF - Journal of Experimental Therapeutics and Oncology

IS - 3

ER -

Cost analysis of intra-arterial versus intra-venous delivery of bevacizumab for the treatment of recurrent glioblastoma multiforme

Abstract

UN SDGs

All Science Journal Classification (ASJC) codes

Other files and links

Fingerprint

Cite this